MedTrace Logo

A Long-term Safety Surveillance Study in Participants Previously Treated With 177Lu-IPN01072

NCT05017662 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2025-09-04

No results posted yet for this study

Summary

The purpose of the protocol is to evaluate the long-term safety of medicine 177Lu-satoreotide tetraxetan (also known as 177Lu-IPN01072 or 177Lu-OPS201) for patients who have previously received 177Lu-satoreotide tetraxetan in the clinical study OPS-C-001 / D-FR-01072-001.

Conditions

Interventions

OTHER

Data collection

Participants will have surveillance visits every 3 months up to 5 years after their first dose of 177Lu-IPN01072 in Study OPS-C-001.

Sponsors & Collaborators

  • Ariceum Therapeutics GmbH

    lead INDUSTRY

Principal Investigators

  • Ariceum Chief Medical Officer · Ariceum

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-14
Primary Completion
2025-04-29
Completion
2025-04-29

Countries

  • Australia
  • Austria
  • Denmark
  • France
  • Switzerland
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05017662 on ClinicalTrials.gov